阿苯達唑驅蟲劑全球市場2022-2029

市場動態

阿苯達唑驅蟲藥治療蠕蟲病的需求擴大

Celrhisis 被稱為人類和其他動物的一種大型寄生蟲病，其中大部分身體都被稱為蠕蟲的寄生蟲侵染。由於蛔蟲、鉤蟲、鞭蟲等，流行率上升預計將推動驅蟲藥市場。作為回報，預計全球經濟規模將有所改善。據世衛組織稱，截至 2020 年 3 月，全世界有近 15 億人遭受土傳蠕蟲感染。這個數字佔全球人口的 24%。蛔蟲（蛔蟲）、Tritula（鞭蟲）、美洲鉤蟲和十二指腸鉤蟲是增加疾病負擔的主要物種（鉤蟲）。根據世衛組織的資料，2020年3月，撒哈拉以南非洲、美洲、中國和亞洲國家的土傳蠕蟲感染分佈較高。例如，國家驅蟲日是印度衛生和家庭福利部政府為使該國無蟲害而做出的一項重大努力。根據世界衛生組織的數據，印度有 2.41 億 1 至 14 歲的兒童感染腸道寄生蟲的風險很高，這些寄生蟲是寄生蟲。預計政府還將就提高認識活動和根除蠕蟲病提出建議。

另一方面，阿苯達唑驅蟲藥的副作用，如頭痛、頸部僵硬、對光的敏感性增加、精神錯亂和發燒，可能會限制市場份額。此外，阿苯達唑可能會增加出血和感染的風險。

全球阿苯達唑驅蟲藥市場報告將提供大約 51 個市場數據表、45 個數字和 190 頁

目錄

第一章調查方法及範圍

• 調查方法
• 市場範圍

第 2 章主要趨勢和發展

第 3 章執行摘要

• 按類型劃分的市場細分
• 按應用劃分的市場細分
• 按地區劃分的市場細分

第 4 章市場動態

• 市場影響因素
  • 驅動程序
  • 約束因素
  • 商機
• 影響分析

第五章行業分析

• 波特五力分析
• 供應鏈分析
• PEST 分析
• 定價分析
• 報銷分析
• 監管分析
• 未滿足的需求
• 專利趨勢

第 6 章 COVID-19 分析

• COVID-19 的市場分析
  • COVID-19 之前的市場情景
  • COVID-19 的當前市場情景
  • COVID-19 後或未來情景
• COVID-19 期間的價格動態
• 供需範圍
• 大流行期間與市場相關的政府舉措
• 製造商的戰略舉措

第 7 章按類型

• 藥片
• 膠囊
• 其他

第 8 章最終用戶

• 人類
• 獸藥

第 9 章按地區

• 北美
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 意大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳大利亞
  • 其他亞太地區
• 中東和非洲

第 10 章競爭格局

• 競爭場景
• 競爭對手戰略分析
• 市場情況/份額分析
• 併購分析

第 11 章公司簡介

• GlaxoSmithKline
  • 公司概況
  • 產品組合和描述
  • 主要亮點
  • 財務摘要
• Fredun Pharmaceuticals Ltd
• Sequent Scientific
• Huazhong Pharmaceutical
• Zhongjia Pharmaceutical
• Jiangsu Qihui
• Salius Pharma
• Lasa Supergenerics Limited
• K.A. Malle Pharmaceuticals
• Supharma Chem

第12章 DataM

Market Overview

Albendazole anthelmintic drug market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Albendazole, also known as albendazole, is an anthelmintic drug. It inhibits the production or replication of new insect larvae (worms) in the body. It is used to combat inflammatory diseases from worms like pork wire and dog tapestry. For various purposes, albendazole can be used in humans and livestock. The capillary disease is caused by Capillary pelican (dogs and cats), and C is used in poultry. Cati Felis (cats). Capillary bladders infect, so they are sometimes referred to as bladder worms. With albendazole. Due to growing neurocysticercosis cases, the demand for albendazole drugs will expand dramatically in the coming years (infection caused by the pork tapeworm in the muscles, brain, and eyes that may cause seizures, brain swelling, and vision problems).

Market Dynamics: Growing demand Albendazole Anthelmintic Drug in the treatment of Helmonthasis

Helmonthasis, also known as worm infection, is a human and other animal macroparasite disease that includes parasite worms in most of the body, known as helminths (helminths). A rise in the prevalence is expected to drive the market for anthelmintic medicine caused by roundworm, hookworm, whipworm and other worms. In exchange, the size of the global economy is projected to improve. According to the WHO, nearly 1.5 billion people worldwide have suffered from soil-borne helminth infection as of March 2020. 24 per cent of the global human population accounts for this figure. Ascaris lumbricoides (roundworms), trichuriasis trichiura (whipworms), necator americanus, and ancylostoma duodenale are major species that raise the disease burden (hookworms). According to WHO info, soil-transmitted helminth infection distribution in Sub-Saharan Africa, the Americas, China and countries in Asia was higher in March 2020. The National Deworming Day, for example, is a big effort by the Government of India's Ministry of Health and Family Welfare to make the nation worm-free. In India, 241 million children aged 1 to 14 years are at higher risk of parasitic intestinal worms, according to the WHO. The government is also expected to establish recommendations for awareness-raising and the eradication of helminth infection.

On the other hand, albendazole anthelmintic drug's side effects, such as headache, neck stiffness, increased sensitivity to light, confusion, and fever, may act as restraint of the market share. Further, Albendazole can increase your risk of bleeding or infection.

Market Segmentation: The tablet albendazole anthelmintic drug segment is projected to be the market's dominant segment during the forecast period

The tablets segment accounts for the largest market share of the global Albendazole Anthelmintic Drug market and is projected to rise during the forecast period at its highest CAGR. The category of tablets and powders is growing primarily because of ease of use and relatively better absorption

Different prevention steps for the management of parasites in animals are being introduced. Veterinarians rely on anthelmintic drugs to protect the animals' health as vaccines are not readily available, and better vaccines have to be developed. Companies take advantage of value capturing opportunities for improved animal health through increased available macrocyclic benzimidazoles and tetrahydro pyrimidines on the anthelmintic drugs market.

Geographical Penetration: North America is the dominating region during the forecast period

In North America, major research and development players will account for the significant share of global albendazole demand for medicines. The USA, for example. The Food and Drug Administration authorized the Cipla Abbreviated New Medication Request for Albendazole Tablets. Further, major players in the region are adopting the product launch to increase the product portfolio and gain competitive market share. Moreover, the demand for albendazole drugs in Asia-Pacific is expected to develop rapidly in the timeframe predicted, as the prevalence of helminthic infection is growing and increasing.

Competitive Landscape:

The albendazole anthelmintic drug market is moderately competitive, owing to major market players in the key regions such as the US, China, India and others. The key albendazole anthelmintic drug players contributing to the growth of the global market include GlaxoSmithKline, Fredun Pharmaceuticals Ltd, Sequent Scientific, Huazhong Pharmaceutical, Zhongjia Pharmaceutical, Jiangsu Qihui, Salius Pharma, Lasa Supergenerics Limited, K.A. Malle Pharmaceuticals, Supharma Chem, among others. The major players are adopting new product launch and expansion strategies for global growth in the albendazole anthelmintic drug market. In June 2020, Pharma major Lupin announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the U.S. FDA, to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories Inc. In April 2021, Dr. Reddy's Laboratories along with its subsidiaries announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, approved by the U.S. Food and Drug Administration (USFDA).

COVID-19 Impact: Positive impact on the global Albendazol Anthelmintic Drug market

With the continuing breakout of coronavirus COVID-19, the unprecedented need for medications to tackle the novel infection has been intensified. As a result, AI, Gero, is recognized as a global expert in AI-driven drug developments and validating promising anthelmintic drug therapy potentials for COVID-19. As a result, the treatment of coronavirus in patients with niclosamide has proven to be successful. It has been approved in the U.S., Italy, France, and a few other countries where active COVID-19 patients are high. With the authorization of niclosamide, the effective use of AI-driven drug development approaches to build upon revenue-generating opportunities in industries on the anthelmintics market increases. Anthelmintic drug market firms are working to carry out clinical trials of existing therapeutic drugs that can be effective for treating coronavirus, which has further led to the demand for albendazole anthelmintic drug.

The global albendazole anthelmintic drug market report would provide an access to approximately 51 market data tables, 45 figures and 190 pages

Table of Contents

Scope and Methodology

• 1.1. Research Methodology
• 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

• 3.1. Market Snippet by Type
• 3.2. Market Snippet by Application
• 3.3. Market Snippet by Region

4. Market Dynamics

• 4.1. Market impacting factors
  • 4.1.1. Drivers
  • 4.1.2. Restraints
  • 4.1.3. Opportunities
• 4.2. Impact analysis

5. Industry Analysis

• 5.1. Porter's five forces analysis
• 5.2. Supply Chain analysis
• 5.3. PEST Analysis
• 5.4. Pricing Analysis
• 5.5. Reimbursement Analysis
• 5.6. Regulatory Analysis
• 5.7. Unmet Needs
• 5.8. Patent Trends

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives

7. By Type

• 7.1. Introduction
  • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Type Segment
  • 7.1.2. Market attractiveness index, By Type Segment
• 7.2. Tablet*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 7.3. Capsule
• 7.4. Others

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Application Segment
  • 8.1.2. Market attractiveness index, By Application Segment
• 8.2. Human*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
• 8.3. Veterinary

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key region-specific dynamics
  • 9.2.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.2.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.3.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Rest of South America
• 9.4. Europe
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.4.5.1. Germany
    • 9.4.5.2. U.K.
    • 9.4.5.3. France
    • 9.4.5.4. Spain
    • 9.4.5.5. Italy
    • 9.4.5.6. Rest of Europe
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application
  • 9.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Application

10. Competitive Landscape

• 10.1. Competitive scenario
• 10.2. Competitor strategy analysis
• 10.3. Market positioning/share analysis
• 10.4. Mergers and acquisitions analysis

11. Company Profiles

• 11.1. GlaxoSmithKline*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Fredun Pharmaceuticals Ltd
• 11.3. Sequent Scientific
• 11.4. Huazhong Pharmaceutical
• 11.5. Zhongjia Pharmaceutical
• 11.6. Jiangsu Qihui
• 11.7. Salius Pharma
• 11.8. Lasa Supergenerics Limited
• 11.9. K.A. Malle Pharmaceuticals
• 11.10. Supharma Chem
• List not Exhaustive*

12. DataM

• 12.1. Appendix
• 12.2. About us and services
• 12.3. Contact us